Skip to main content
SpringerLink
Log in

Postmarketing safety reports for the collagenase-based product Xiaflex [Xiapex] show no unexpected findings,

  • Media release
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. BioSpecifics Technologies Corp.BioSpecifics Technologies Corp. Announces 30 Month Safety Update for XIAFLEX(Rm) in Dupuytren's Contracture Media Release: 5 Sep 2012. Available from: URL: http://www.biospecifics.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Postmarketing safety reports for the collagenase-based product Xiaflex [Xiapex] show no unexpected findings,. React. Wkly. 1420, 3 (2012). https://doi.org/10.2165/00128415-201214200-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201214200-00005

Keywords

Search

Navigation